3-[3,3-difluoro-7-(8-methyl-1H-1,3,5-triazonin-9-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
C16H18F2N6O — CID 166688543
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[3,3-difluoro-7-(8-methyl-1H-1,3,5-triazonin-9-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
3-[3,3-difluoro-7-(8-methyl-1H-1,3,5-triazonin-9-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile (PubChem CID 166688543) has the molecular formula C16H18F2N6O and a molecular weight of 348.36 g/mol. Its IUPAC name is 3-[3,3-difluoro-7-(8-methyl-1H-1,3,5-triazonin-9-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile.
Molecular Properties
| Compound Name | 3-[3,3-difluoro-7-(8-methyl-1H-1,3,5-triazonin-9-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile |
|---|---|
| PubChem CID | 166688543 |
| Molecular Formula | C16H18F2N6O |
| Molecular Weight | 348.36 g/mol |
| Exact Mass | 348.15 |
| IUPAC Name | 3-[3,3-difluoro-7-(8-methyl-1H-1,3,5-triazonin-9-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile |
| SMILES | Cc1ccncnc[nH]c1N1CCC2(C1)N(C(=O)CC#N)CC2(F)F |
| InChI | InChI=1S/C16H18F2N6O/c1-12-3-6-20-10-21-11-22-14(12)23-7-4-15(8-23)16(17,18)9-24(15)13(25)2-5-19/h3,6,10-11H,2,4,7-9H2,1H3,(H,20,21,22)/b6-3-,14-12+ |
| InChIKey | LLJSOJCSUSPWDC-ITXHFHFKSA-N |
| XLogP | 1.58 |
| TPSA | 88.91 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 25 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 348.36 |
| LogP ≤ 5 | 1.58 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166688543 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.